The indications from both our preclinical animal experiments and initial data from trials in adult patients supports the view that DS-3032b achieves MDM2 inhibition with fewer toxic side effects, and is likely a promising MDM2 small molecule inhibitor for entry into pediatric patient trials for neuroblastoma. The gene discussed is MDM2; the disease is neuroblastoma.